CTOs on the Move

Whitmyer Biomechanix

www.whitbio.com

 
Whitmyer Biomechanix is a Tallahassee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.whitbio.com
  • 3373 Garber Dr
    Tallahassee, FL USA 32303
  • Phone: 850.656.9448

Executives

Name Title Contact Details

Similar Companies

Just-Evotec Biologics

Just Evotec Biologics is an integrated design company that delivers advanced biotherapeutics discovery, CDMO capabilities and FIH to commercial manufacturing. They focus on accelerating and expanding access to biotherapeutics through scientific and tec...

Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

Cerulean

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.

Conagen

Conagen is a #syntheticbiology leader, supporting our global partners through #enzymatic and #microbial platforms and #biomanufacturing capabilities.

PrimeGen Biotech

PrimeGen Biotech LLC is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.